AccuSift provides high‑performance rosiglitazone competitive assay pairings, characterized by exceptional batch‑to‑batch consistency and optimized for IVD kit development (Lateral Flow, Chemiluminescence, ELISA, POCT). These pairings offer high affinity and specificity, facilitating rapid detection.Rosiglitazone lowers blood glucose by increasing insulin sensitivity in skeletal muscle, liver, and adipose tissue, thereby enhancing cellular glucose utilization. It significantly reduces fasting blood glucose, insulin, and C‑peptide levels, and also lowers postprandial blood glucose and insulin.On October 27, 2017, the World Health Organization’s International Agency for Research on Cancer (IARC) listed rosiglitazone in its preliminary compilation of Group 3 carcinogens.Performance Characteristics:
Sensitivity: ELISA IC50: 2 ppb
Source: Mouse Monoclonal Antibody
Recommended Pairing: (Coating) / (Labeling)
Storage: Long‑term storage at ≤ –20°C; short‑term storage at 2–8°C. Shipped on ice packs.
WeChat
